Literature DB >> 25435054

Dose regimen of favipiravir for Ebola virus disease.

France Mentré1, Anne-Marie Taburet2, Jeremie Guedj3, Xavier Anglaret4, Sakoba Keïta5, Xavier de Lamballerie6, Denis Malvy4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25435054     DOI： 10.1016/S1473-3099(14)71047-3

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  36 in total

1.  Non-specific anti-viral approach towards Ebola virus infection: a comment on "Against Ebola: type I interferon guard risk and mesenchymal stromal cell combat sepsis".

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  J Zhejiang Univ Sci B       Date:  2015-03       Impact factor: 3.066

2.  Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses.

Authors:  Vincent Madelain; Jérémie Guedj; France Mentré; Thi Huyen Tram Nguyen; Frédéric Jacquot; Lisa Oestereich; Takumi Kadota; Koichi Yamada; Anne-Marie Taburet; Xavier de Lamballerie; Hervé Raoul
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

3.  Successful treatment of Marburg virus with orally administrated T-705 (Favipiravir) in a mouse model.

Authors:  Wenjun Zhu; Zirui Zhang; Shihua He; Gary Wong; Logan Banadyga; Xiangguo Qiu
Journal:  Antiviral Res       Date:  2018-02-03       Impact factor: 5.970

Review 4.  Clinical Evaluation of Ebola Virus Disease Therapeutics.

Authors:  Guodong Liu; Gary Wong; Shuo Su; Yuhai Bi; Frank Plummer; George F Gao; Gary Kobinger; Xiangguo Qiu
Journal:  Trends Mol Med       Date:  2017-08-17       Impact factor: 11.951

Review 5.  Towards antivirals against chikungunya virus.

Authors:  Rana Abdelnabi; Johan Neyts; Leen Delang
Journal:  Antiviral Res       Date:  2015-06-25       Impact factor: 5.970

6.  Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase.

Authors:  Rana Abdelnabi; Ana Theresa Silveira de Morais; Pieter Leyssen; Isabelle Imbert; Stéphanie Beaucourt; Hervé Blanc; Mathy Froeyen; Marco Vignuzzi; Bruno Canard; Johan Neyts; Leen Delang
Journal:  J Virol       Date:  2017-05-26       Impact factor: 5.103

Review 7.  Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.

Authors:  Vincent Madelain; Thi Huyen Tram Nguyen; Anaelle Olivo; Xavier de Lamballerie; Jérémie Guedj; Anne-Marie Taburet; France Mentré
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

8.  Zika Virus Replication Is Substantially Inhibited by Novel Favipiravir and Interferon Alpha Combination Regimens.

Authors:  Camilly P Pires de Mello; Xun Tao; Tae Hwan Kim; Jürgen B Bulitta; Jaime L Rodriquez; Justin J Pomeroy; Ashley N Brown
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

9.  A response adaptive randomization platform trial for efficient evaluation of Ebola virus treatments: A model for pandemic response.

Authors:  Scott M Berry; Elizabeth A Petzold; Peter Dull; Nathan M Thielman; Coleen K Cunningham; G Ralph Corey; Micah T McClain; David L Hoover; James Russell; J McLeod Griffiss; Christopher W Woods
Journal:  Clin Trials       Date:  2016-01-14       Impact factor: 2.486

Review 10.  Ebola virus disease: an update on post-exposure prophylaxis.

Authors:  William A Fischer; Pauline Vetter; Daniel G Bausch; Timothy Burgess; Richard T Davey; Robert Fowler; Frederick G Hayden; Peter B Jahrling; Andre C Kalil; Douglas L Mayers; Aneesh K Mehta; Timothy M Uyeki; Michael Jacobs
Journal:  Lancet Infect Dis       Date:  2017-11-15       Impact factor: 25.071
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.